上海柏全生物

Shanghai Boquan Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class (FIC) therapeutic antibodies for oncology. The company leverages its proprietary target discovery platform to identify novel cell-surface targets and develop highly specific monoclonal and bispecific antibodies. Its lead programs target B7 family members and other immune-modulating proteins to address unmet needs in solid tumors. The company's lead candidate, BQ001, is a monoclonal antibody targeting CD276 (B7-H3) currently in Phase 1 clinical trials. Boquan Biotech is backed by prominent venture capital firms including Matrix Partners China and GL Ventures. The firm aims to translate deep biological insights into transformative precision medicines for cancer patients.